Rights Issue15 May 2026, 02:43 pm
Solara: No Deviation in Rights Issue Funds for March 2026 Quarter
AI Summary
Solara Active Pharma Sciences Limited reported no deviation or variation in the use of proceeds raised through its Rights Issue for the quarter ended March 31, 2026. This confirmation complies with Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Audit Committee reviewed and approved the statement of utilization of proceeds without any comments.
Key Highlights
- Solara confirms no deviation in funds raised via Rights Issue for Q4 2026.
- Compliance with SEBI Regulation 32 regarding use of Rights Issue proceeds.
- Audit Committee approved the statement without comments on May 15, 2026.
- ₹309.79 Crores was raised through the Rights Issue.
- CRISIL Ratings Limited is the monitoring agency.
Price Impact
More from SOLARA